OBJECTIVES:Interferon gamma (IFN-gamma) is a pleiotropic cytokine with antiproliferative, immunostimulatory, and chemosensitization properties. This trial was designed to evaluate IFN-gamma 1b plus carboplatin and paclitaxel in treatment-naive ovarian cancer (OC) and primary peritoneal carcinoma (PPC) patients. METHODS:Eligible patients were randomized to 6 cycles of carboplatin/paclitaxel every 3 weeks or the same in combination with IFN-gamma 1b (100 microg 3x/wk subcutaneously). The primary endpoint was overall survival (OS) time (target hazard ratio (HR)=0.77). Secondary endpoints included progression-free survival (target HR=0.7), based on blinded review of serial imaging scans, physical exams, and CA-125 levels. RESULTS:847 patients were enrolled (OC 774, PPC 73) in Europe (n=539) and North/South America (n=308) from January 29, 2002 to March 31, 2004 and stratified according to: optimal debulking (n=271) versussuboptimal debulking with plans for interval debulking (PID) (n=238) or no PID (n=338). The study stopped early following a protocol-defined second interim analysis which revealed significantly shorter OS time in patients receiving IFN-gamma 1b plus chemotherapy compared to chemotherapy alone (1138 days vs. not estimable, HR=1.45, 95% CI=1.15-1.83). At the time of the analysis, 169 of 426 (39.7%) patients in the IFN-gamma 1b plus chemotherapy group had died compared to 128 of 421 (30.4%) in the chemotherapy alone group. Serious adverse events were more common in the IFN-gamma 1b plus chemotherapy group (48.5% vs. 35.4%), primarily due to a higher incidence of serious hematological toxicities (34.5% vs. 22.7%). CONCLUSIONS: Treatment with IFN-gamma 1b in combination with carboplatin/paclitaxel does not have a role in the first-line treatment of advanced ovarian cancer.
RCT Entities:
OBJECTIVES:Interferon gamma (IFN-gamma) is a pleiotropic cytokine with antiproliferative, immunostimulatory, and chemosensitization properties. This trial was designed to evaluate IFN-gamma 1b plus carboplatin and paclitaxel in treatment-naive ovarian cancer (OC) and primary peritoneal carcinoma (PPC) patients. METHODS: Eligible patients were randomized to 6 cycles of carboplatin/paclitaxel every 3 weeks or the same in combination with IFN-gamma 1b (100 microg 3x/wk subcutaneously). The primary endpoint was overall survival (OS) time (target hazard ratio (HR)=0.77). Secondary endpoints included progression-free survival (target HR=0.7), based on blinded review of serial imaging scans, physical exams, and CA-125 levels. RESULTS: 847 patients were enrolled (OC 774, PPC 73) in Europe (n=539) and North/South America (n=308) from January 29, 2002 to March 31, 2004 and stratified according to: optimal debulking (n=271) versus suboptimal debulking with plans for interval debulking (PID) (n=238) or no PID (n=338). The study stopped early following a protocol-defined second interim analysis which revealed significantly shorter OS time in patients receiving IFN-gamma 1b plus chemotherapy compared to chemotherapy alone (1138 days vs. not estimable, HR=1.45, 95% CI=1.15-1.83). At the time of the analysis, 169 of 426 (39.7%) patients in the IFN-gamma 1b plus chemotherapy group had died compared to 128 of 421 (30.4%) in the chemotherapy alone group. Serious adverse events were more common in the IFN-gamma 1b plus chemotherapy group (48.5% vs. 35.4%), primarily due to a higher incidence of serious hematological toxicities (34.5% vs. 22.7%). CONCLUSIONS: Treatment with IFN-gamma 1b in combination with carboplatin/paclitaxel does not have a role in the first-line treatment of advanced ovarian cancer.
Authors: Shihong Zhang; Karan Kohli; R Graeme Black; Lu Yao; Sydney M Spadinger; Qianchuan He; Venu G Pillarisetty; Lee D Cranmer; Brian A Van Tine; Cassian Yee; Robert H Pierce; Stanley R Riddell; Robin L Jones; Seth M Pollack Journal: Cancer Immunol Res Date: 2019-06-06 Impact factor: 11.151
Authors: Christine M Fam; Stephen P Eisenberg; Sharon J Carlson; Elizabeth A Chlipala; George N Cox; Mary S Rosendahl Journal: J Interferon Cytokine Res Date: 2014-05-19 Impact factor: 2.607
Authors: Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos Journal: Gynecol Oncol Date: 2009-12-02 Impact factor: 5.482
Authors: Kathleen M Schmeler; Saroj Vadhan-Raj; Pedro T Ramirez; Sachin M Apte; Lorenzo Cohen; Roland L Bassett; Revathy B Iyer; Judith K Wolf; Charles L Levenback; David M Gershenson; Ralph S Freedman Journal: Gynecol Oncol Date: 2009-03-04 Impact factor: 5.482
Authors: Natalie J Neubert; Martina Schmittnaegel; Natacha Bordry; Sina Nassiri; Noémie Wald; Christophe Martignier; Laure Tillé; Krisztian Homicsko; William Damsky; Hélène Maby-El Hajjami; Irina Klaman; Esther Danenberg; Kalliopi Ioannidou; Lana Kandalaft; George Coukos; Sabine Hoves; Carola H Ries; Silvia A Fuertes Marraco; Periklis G Foukas; Michele De Palma; Daniel E Speiser Journal: Sci Transl Med Date: 2018-04-11 Impact factor: 17.956